| Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study |
Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction, Questionnaire Administration |
Recruiting |
| Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia |
Curcumin, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment |
Active, not recruiting |
| Chemoprevention of Gastric Carcinogenesis |
Eflornithine, Eflornithine placebo |
Active, not recruiting |
| DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection |
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid |
Active, not recruiting |
| CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts |
Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture |
Active, not recruiting |
| Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps |
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline |
Active, not recruiting |
| ASPirin Intervention for the REDuction of Colorectal Cancer Risk |
Placebo for Aspirin, Aspirin |
Active, not recruiting |
| The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) |
Placebo, Sulindac 400 MG |
Recruiting |